Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H24N2O3 |
Molecular Weight | 352.4269 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12C[C@]3([H])C(=CO[C@@H](C)[C@@]3([H])CN1CCC4=C2NC5=CC=CC=C45)C(=O)OC
InChI
InChIKey=GRTOGORTSDXSFK-XJTZBENFSA-N
InChI=1S/C21H24N2O3/c1-12-16-10-23-8-7-14-13-5-3-4-6-18(13)22-20(14)19(23)9-15(16)17(11-26-12)21(24)25-2/h3-6,11-12,15-16,19,22H,7-10H2,1-2H3/t12-,15-,16+,19-/m0/s1
Molecular Formula | C21H24N2O3 |
Molecular Weight | 352.4269 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
The Rauwolfia alkaloid, raubasine (ajmalicine), has been found to have broad application in the treatment of circulatory diseases, especially in the relief of obstruction of normal cerebral blood flow. In combination with other Rauwolfia alkaloids it has been used to lower high blood pressure. Raubasine is an antihypertensive drug used in the treatment of high blood pressure. It has been marketed under numerous brand names including Card-Lamuran, Circolene, Cristanyl, Duxil, Duxor, Hydroxysarpon, Iskedyl, Isosarpan, Isquebral, Lamuran, Melanex, Saltucin Co, Salvalion, and Sarpan. Raubasine acts as a α1-adrenergic receptor antagonist.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1867 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7562902 |
8.2 nM [Ki] | ||
Target ID: CHEMBL1916 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7562902 |
5.0 nM [Ki] | ||
Target ID: CHEMBL1942 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7562902 |
14.5 nM [Ki] | ||
Target ID: CHEMBL1907610 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3021076 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Lamuran Approved UseRAUBASINE is an antihypertensive drug used in the treatment of high blood pressure. |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Evaluation of natural products as inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. | 1991 Jan-Feb |
|
Biliary drug lithiasis: dipyridamole gallstones. | 1992 Nov 28 |
|
Cytochrome P450 2D6 (CYP2D6) inhibitory constituents of Catharanthus roseus. | 2005 Jun |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/790125
In the raubasine group (10 patients aged 47 to 81 years, including 6 cases of anacidity) there was after one and two weeks treatment with dialy doses of 90 mg raubasine a significant reduction of the raised vascular resistance and pulsewave velocity and systolic blood pressure in the internal carotid artery which indicate an improvement in cerebral haemodynamics.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3089826
In strips of isolated canine basilar arteries, previously labeled with 3 X 10(-7) M of either [3H]noradrenaline or [3H]serotonin, three consecutive periods of electrical stimulation (2 Hz) evoked a reproducible overflow of the respective [3H]amine. Increasing concentrations of raubasine (7.5 X 10(-7)-7.5 X 10(-6) M) did not influence the spontaneous 3H efflux but increased the stimulation-induced 3H overflow in a concentration-dependent way. The highest concentration of raubasine used (2.5 X 10(-5) M) caused an increased spontaneous 3H efflux but no longer augmented the stimulation-induced 3H overflow.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:19:54 GMT 2023
by
admin
on
Fri Dec 15 15:19:54 GMT 2023
|
Record UNII |
4QJL8OX71Z
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
441975
Created by
admin on Fri Dec 15 15:19:54 GMT 2023 , Edited by admin on Fri Dec 15 15:19:54 GMT 2023
|
PRIMARY | |||
|
483-04-5
Created by
admin on Fri Dec 15 15:19:54 GMT 2023 , Edited by admin on Fri Dec 15 15:19:54 GMT 2023
|
PRIMARY | |||
|
8746
Created by
admin on Fri Dec 15 15:19:54 GMT 2023 , Edited by admin on Fri Dec 15 15:19:54 GMT 2023
|
PRIMARY | |||
|
2524
Created by
admin on Fri Dec 15 15:19:54 GMT 2023 , Edited by admin on Fri Dec 15 15:19:54 GMT 2023
|
PRIMARY | |||
|
100000078609
Created by
admin on Fri Dec 15 15:19:54 GMT 2023 , Edited by admin on Fri Dec 15 15:19:54 GMT 2023
|
PRIMARY | |||
|
Raubasine
Created by
admin on Fri Dec 15 15:19:54 GMT 2023 , Edited by admin on Fri Dec 15 15:19:54 GMT 2023
|
PRIMARY | |||
|
SUB15107MIG
Created by
admin on Fri Dec 15 15:19:54 GMT 2023 , Edited by admin on Fri Dec 15 15:19:54 GMT 2023
|
PRIMARY | |||
|
4QJL8OX71Z
Created by
admin on Fri Dec 15 15:19:54 GMT 2023 , Edited by admin on Fri Dec 15 15:19:54 GMT 2023
|
PRIMARY | |||
|
DTXSID60904151
Created by
admin on Fri Dec 15 15:19:54 GMT 2023 , Edited by admin on Fri Dec 15 15:19:54 GMT 2023
|
PRIMARY | |||
|
72133
Created by
admin on Fri Dec 15 15:19:54 GMT 2023 , Edited by admin on Fri Dec 15 15:19:54 GMT 2023
|
PRIMARY | |||
|
m9507
Created by
admin on Fri Dec 15 15:19:54 GMT 2023 , Edited by admin on Fri Dec 15 15:19:54 GMT 2023
|
PRIMARY | Merck Index | ||
|
142527
Created by
admin on Fri Dec 15 15:19:54 GMT 2023 , Edited by admin on Fri Dec 15 15:19:54 GMT 2023
|
PRIMARY | |||
|
207-589-5
Created by
admin on Fri Dec 15 15:19:54 GMT 2023 , Edited by admin on Fri Dec 15 15:19:54 GMT 2023
|
PRIMARY | |||
|
17205
Created by
admin on Fri Dec 15 15:19:54 GMT 2023 , Edited by admin on Fri Dec 15 15:19:54 GMT 2023
|
PRIMARY | RxNorm |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |